Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice

Mads Kreilgaard; D G Smith; L T Brennum; C Sánchez

doi:10.1038/bjp.2008.243

Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice

Mads Kreilgaard, D G Smith, L T Brennum, C Sánchez

LUKKET: Pharmacotherapy

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

40 Citationer (Scopus)

Abstract

Bridging the gap between preclinical research and clinical trials is vital for drug development. Predicting clinically relevant steady-state drug concentrations (Css) in serum from preclinical animal models may facilitate this transition. Here we used a pharmacokinetic/pharmacodynamic (PK/PD) modelling approach to evaluate the predictive validity of 5-hydroxytryptamine (5-HT; serotonin) transporter (SERT) occupancy and 5-hydroxytryptophan (5-HTP)-potentiated behavioral syndrome induced by 5-HT reuptake inhibitor (SRI) antidepressants in mice.

Originalsprog	Engelsk
Tidsskrift	British Journal of Pharmacology
Vol/bind	155
Udgave nummer	2
Sider (fra-til)	276-84
Antal sider	9
ISSN	0007-1188
DOI	https://doi.org/10.1038/bjp.2008.243
Status	Udgivet - sep. 2008

Adgang til dokumentet

10.1038/bjp.2008.243

Citationsformater

@article{4c640f63a86a4be88b3031fbff569c21,

title = "Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice",

abstract = "Bridging the gap between preclinical research and clinical trials is vital for drug development. Predicting clinically relevant steady-state drug concentrations (Css) in serum from preclinical animal models may facilitate this transition. Here we used a pharmacokinetic/pharmacodynamic (PK/PD) modelling approach to evaluate the predictive validity of 5-hydroxytryptamine (5-HT; serotonin) transporter (SERT) occupancy and 5-hydroxytryptophan (5-HTP)-potentiated behavioral syndrome induced by 5-HT reuptake inhibitor (SRI) antidepressants in mice.",

keywords = "Animals, Citalopram, Male, Mice, Models, Biological, Paroxetine, Serotonin, Serotonin Uptake Inhibitors, Sertraline",

author = "Mads Kreilgaard and Smith, {D G} and Brennum, {L T} and C S{\'a}nchez",

year = "2008",

month = sep,

doi = "10.1038/bjp.2008.243",

language = "English",

volume = "155",

pages = "276--84",

journal = "British Journal of Pharmacology",

issn = "0007-1188",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice

AU - Kreilgaard, Mads

AU - Smith, D G

AU - Brennum, L T

AU - Sánchez, C

PY - 2008/9

Y1 - 2008/9

N2 - Bridging the gap between preclinical research and clinical trials is vital for drug development. Predicting clinically relevant steady-state drug concentrations (Css) in serum from preclinical animal models may facilitate this transition. Here we used a pharmacokinetic/pharmacodynamic (PK/PD) modelling approach to evaluate the predictive validity of 5-hydroxytryptamine (5-HT; serotonin) transporter (SERT) occupancy and 5-hydroxytryptophan (5-HTP)-potentiated behavioral syndrome induced by 5-HT reuptake inhibitor (SRI) antidepressants in mice.

AB - Bridging the gap between preclinical research and clinical trials is vital for drug development. Predicting clinically relevant steady-state drug concentrations (Css) in serum from preclinical animal models may facilitate this transition. Here we used a pharmacokinetic/pharmacodynamic (PK/PD) modelling approach to evaluate the predictive validity of 5-hydroxytryptamine (5-HT; serotonin) transporter (SERT) occupancy and 5-hydroxytryptophan (5-HTP)-potentiated behavioral syndrome induced by 5-HT reuptake inhibitor (SRI) antidepressants in mice.

KW - Animals

KW - Citalopram

KW - Male

KW - Mice

KW - Models, Biological

KW - Paroxetine

KW - Serotonin

KW - Serotonin Uptake Inhibitors

KW - Sertraline

U2 - 10.1038/bjp.2008.243

DO - 10.1038/bjp.2008.243

M3 - Journal article

C2 - 18552871

VL - 155

SP - 276

EP - 284

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -